Sign up
Pharma Capital
Market: AIM
52-week High/Low: 48.62p / 6.52p
Sector: Pharma & Biotech
Market Cap: 13.81M

Futura Medical is a pharmaceutical group that develops innovative products for both the prescription and consumer healthcare markets

We are experts in transdermal delivery and have developed an advanced proprietary transdermal technology, DermaSys®. We are developing a portfolio of products in pain relief and sexual health and our strategy is to license their manufacture and...

Futura Medical PLC

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Futura Medical PLC

Futura Medical PLC Snapshot

Futura's innovation strategy applies advanced science to develop products with compelling commercial potential using our advanced proprietary transdermal technology.

Based in Surrey, UK, the company's shares trade on the AIM market of the London Stock Exchange. Futura's development pipeline focuses on sexual healthcare and pain relief management and we are evaluating further therapeutic opportunities as potential additions to the pipeline. Futura is gaining recognition within the pharmaceutical industry for its strengths in transdermal drug delivery technology. We have relationships with a number of key players in the consumer healthcare market.

Futura is actively working to expand its product portfolio both through internal product development and externally through focused product acquisition. If you believe you have a product under development that would be of interest to us, please write to Futura Medical Developments Limited, Surrey Technology Centre, 40 Occam Road, Guildford, Surrey, GU2 7YG or email us at [email protected]

Our Products
Futura's innovation strategy applies advanced science to develop products with compelling commercial potential using our advanced proprietary transdermal technology.

Our research and development strategy
We focus exclusively on topically applied pharmaceutical drugs, ancillary medicinal substances and functional excipients for the over the counter and prescription markets. We only incorporate existing well-characterised chemical entities into our products. This strategy gives us a lower development risk profile compared with developing new chemical entities. As a result, the overall risk of the investment is reduced as our strategy increases the likelihood of regulatory approval and lowers the cost of development.

For further infromation please click here

John Clarke
Non-Executive Chairman and Chairman of Nomination Committee

Current roles: John Clarke became Chairman of Futura Medical plc in 2012. He is a member of the Nominations Committee and the Remuneration Committee. He is also the Non-Executive Chairman of Science in Sport plc and Kind Consumer Holdings Limited and a senior advisor to Helios Investment Partners LLP.

Past roles: Appointed President of GSK Consumer Healthcare in 2006, a position from which he stepped down in 2011. Under his leadership, GSK Consumer Healthcare became one of the fastest-growing companies in its industry. Non-executive Chairman of Quantum Pharma Plc.


James Barder
Chief Executive

Current roles: James Barder joined the Group as Chief Executive in 2001. He assists the Remuneration Committee and the Nominations Committee (but is not a member of and does not vote on either). He has overall responsibility for all activities of the Group, is a principal contact for shareholder and investor relations matters and leads commercial negotiations. He first became involved with the Group in 1997.

Past roles: Managing Director of Aon Capital Markets Limited and Non-Executive Director of Lorega Limited. James has predominantly worked in the field of insurance and finance including firms he founded.

Brings to the Board: Over 25 years of experience in setting up, managing and running companies.

Brings to the Board: Extensive experience of the healthcare sector, having worked at GSK for more than 35 years.


Angela Hildreth
Finance Director and Chief Operating Officer
Company Secretary

Current roles: Angela joined the company in February 2018. She leads the Group's finance, HR and IT functions, inputs into commercial and financial strategy, ensures its compliance procedures and is a principal contact for shareholder and investor relations matters.

Past roles: Senior financial roles in a diverse range of industries, including the past 7 years as UK Finance Director at Shield Therepeutics Plc listed on AIM stock exchange.

Brings to the Board: Strategic and operational financial experience of developing and commercialising pharmaceutical products.

For further information click here 

For information on shares plese click here

+44 (0)1483 685 670

Address: Surrey Technology Centre,

40 Occam Road,

Surrey Research Park,

Guildford, Surrey

Nominated Adviser and broker N+1 Singer
1 Bartholomew Lane
London EC2N 2AX
Auditors BDO LLP

Kings Wharf
20-30 Kings Road
Berkshire RG1 3EX
Registrars Capita Asset Services
The Registry
34 Beckenham Road
Principal solicitors Memery Crystal LLP
44 Southampton Buildings
London WC2A 1AP
Patent attorneys Withers and Rogers LLP
4 More London Riverside
Principal bankers HSBC Bank
PO Box 160
12A North Street

View full FUM profile View Profile
View All

Market Reports Including FUM


Executive video interviews


© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.